HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Padayatty, S. J Articles by Levine, M. Search for Related Content PubMed PubMed Citation Articles by Padayatty, S. J Articles by Levine, M.

Reevaluation of Ascorbate in Cancer Treatment: Emerging Evidence, Open Minds and Serendipity

Molecular and Clinical Nutrition Section
Digestive Diseases Branch
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health,
Bethesda, Maryland

ABSTRACT

Some clinicians and alternative therapy practitioners advocate megadose intravenous and oral ascorbate treatment of cancer. Randomized control studies using oral ascorbate showed no benefit. Recent data show that intravenous but not oral administration of ascorbate can produce millimolar plasma concentrations, which are toxic to many cancer cell lines. We propose that ascorbate treatment of cancer should be reexamined by rigorous scientific scrutiny in the light of new evidence.

Key words: cancer, ascorbate, plasma concentration, intravenous, cytotoxicity, vitamin C

This article has been cited by other articles:

				Q. Chen, M. G. Espey, A. Y. Sun, C. Pooput, K. L. Kirk, M. C. Krishna, D. B. Khosh, J. Drisko, and M. Levine From the Cover: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice PNAS, August 12, 2008; 105(32): 11105 - 11109. [Abstract] [Full Text] [PDF]

				J. Lykkesfeldt Ascorbate and Dehydroascorbic Acid as Reliable Biomarkers of Oxidative Stress: Analytical Reproducibility and Long-term Stability of Plasma Samples Subjected to Acidic Deproteinization Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2513 - 2516. [Abstract] [Full Text] [PDF]

				Q. Chen, M. G. Espey, A. Y. Sun, J.-H. Lee, M. C. Krishna, E. Shacter, P. L. Choyke, C. Pooput, K. L. Kirk, G. R. Buettner, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo PNAS, May 22, 2007; 104(21): 8749 - 8754. [Abstract] [Full Text] [PDF]

				S. J. Padayatty, H. D. Riordan, S. M. Hewitt, A. Katz, L. J. Hoffer, and M. Levine Intravenously administered vitamin C as cancer therapy: three cases. Can. Med. Assoc. J., March 28, 2006; 174(7): 937 - 942. [Abstract] [Full Text] [PDF]

				W. Zou, P. Yue, N. Lin, M. He, Z. Zhou, S. Lonial, F. R. Khuri, B. Wang, and S.-Y. Sun Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells Clin. Cancer Res., January 1, 2006; 12(1): 273 - 280. [Abstract] [Full Text] [PDF]

				Q. Chen, M. G. Espey, M. C. Krishna, J. B. Mitchell, C. P. Corpe, G. R. Buettner, E. Shacter, and M. Levine Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues PNAS, September 20, 2005; 102(38): 13604 - 13609. [Abstract] [Full Text] [PDF]

				S. J. Padayatty, M. Levine, P. Kaufmann, P. G. Camici, T. Gnecchi-Ruscone, M. di Terlizzi, T. F. Luscher, and K. P. Schafers Vitamin C and Coronary Microcirculation Response Circulation, June 12, 2001; 103 (23): e117 - e117. [Full Text] [PDF]